« Return to News | Awards & Advancement

Insmed appoints Hayden, Jr. as executive chairman

Thursday, May 17, 2012 10:45 AM

Insmed, a Monmouth Junction, N.J.-based biopharmaceutical company focused on inhalants, has appointed Donald J. Hayden, Jr. as executive chairman of the company's board of directors.

Hayden has served as chairman of Insmed’s board of directors since December 2010.  In his new role, Hayden will continue to work closely with Insmed’s president and CEO Timothy Whitten, and the management team, in executing on the development plan for the company's lead product, Arikace (liposomal amikacin for inhalation).  He will also focus more directly on strategic planning and corporate development.

Hayden joined Insmed following the 2010 merger with Transave, where he had served as executive chairman since 2006. Prior to that position, Hayden had a 25-year career with Bristol-Myers Squibb, where he served in key executive roles, including president of global pharmaceuticals, executive vice president and president of Americas, executive vice president of the health care group and several others. Currently, Hayden also serves as lead independent director of Amicus Therapeutics and director of Otsuka Pharmaceuticals. In addition, he serves in board roles for several privately-held companies, including executive chairman of Azelon Pharmaceuticals, chairman of Vitae Pharmaceuticals and Satori Pharmaceuticals and director of Nora Therapeutics.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.